FR15C0073I2 - Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti) - Google Patents

Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Info

Publication number
FR15C0073I2
FR15C0073I2 FR15C0073C FR15C0073C FR15C0073I2 FR 15C0073 I2 FR15C0073 I2 FR 15C0073I2 FR 15C0073 C FR15C0073 C FR 15C0073C FR 15C0073 C FR15C0073 C FR 15C0073C FR 15C0073 I2 FR15C0073 I2 FR 15C0073I2
Authority
FR
France
Prior art keywords
reverse transcriptase
nucleoside reverse
transcriptase inhibitor
nnrti
nrti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0073C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0073(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR15C0073I1 publication Critical patent/FR15C0073I1/fr
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Application granted granted Critical
Publication of FR15C0073I2 publication Critical patent/FR15C0073I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR15C0073C 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti) Active FR15C0073I2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP04787096.9A EP1663240B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (2)

Publication Number Publication Date
FR15C0073I1 FR15C0073I1 (xx) 2015-04-12
FR15C0073I2 true FR15C0073I2 (fr) 2016-02-12

Family

ID=34280181

Family Applications (3)

Application Number Title Priority Date Filing Date
FR15C0071C Active FR15C0071I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0072C Active FR15C0072I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0073C Active FR15C0073I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
FR15C0071C Active FR15C0071I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0072C Active FR15C0072I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Country Status (25)

Country Link
US (9) US20080200435A1 (xx)
EP (1) EP1663240B2 (xx)
JP (3) JP5507791B2 (xx)
KR (1) KR20060090658A (xx)
CN (1) CN101060844B (xx)
AP (1) AP2109A (xx)
AU (5) AU2004268390B2 (xx)
BE (1) BE2015C053I2 (xx)
CA (1) CA2537095C (xx)
CY (5) CY2015040I2 (xx)
FI (1) FI1663240T4 (xx)
FR (3) FR15C0071I2 (xx)
HK (1) HK1092698A1 (xx)
HR (1) HRP20150798T4 (xx)
HU (5) HUS1500054I1 (xx)
IL (2) IL173438A (xx)
LT (2) LTPA2016045I1 (xx)
LU (3) LU92853I2 (xx)
MX (1) MXPA06002437A (xx)
MY (1) MY169670A (xx)
NL (2) NL300781I2 (xx)
NO (6) NO334877B1 (xx)
NZ (1) NZ545306A (xx)
PL (1) PL1663240T5 (xx)
WO (1) WO2005021001A1 (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
SG155885A1 (en) * 2004-09-02 2009-10-29 Janssen Pharmaceutica Nv Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
ES2384715T3 (es) * 2004-09-02 2012-07-11 Janssen Pharmaceutica Nv Fumarato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
BRPI0514871A (pt) * 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
KR101284361B1 (ko) * 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
CA2577273C (en) * 2004-09-02 2013-11-19 Janssen Pharmaceutica N.V. Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
AP2008004533A0 (en) * 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
CN103877091A (zh) * 2006-01-20 2014-06-25 泰博特克药品有限公司 用tcm278对hiv感染进行的长期治疗
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
US20110046091A1 (en) * 2008-01-03 2011-02-24 Universite De La Medierannee, Aix-Marseille Ii Jardin Du Pharo 58, Boulevard Charles Livon Composition and methods used during anti-hiv treatment
US20110256206A1 (en) * 2008-12-24 2011-10-20 Schachter Deborah M Implantable devices for treating hiv
SG181759A1 (en) 2009-12-21 2012-07-30 Janssen R & D Ireland Degradable removable implant for the sustained release of an active compound
ES2969969T3 (es) 2010-01-27 2024-05-23 Viiv Healthcare Co Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH
CN106511357A (zh) * 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
UY35213A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
WO2018077815A1 (en) 2016-10-24 2018-05-03 Janssen Sciences Ireland Uc Dispersible compositions
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
RU2019136678A (ru) * 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
JP2023503403A (ja) 2019-11-29 2023-01-30 シピオ ライフ サイエンシズ リミテッド リルピビリンを含む組成物及び腫瘍又は癌を治療するためのその使用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
WO1992001453A1 (en) 1990-07-19 1992-02-06 Otsuka Pharmaceutical Co., Ltd. Solid preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2121129A1 (en) * 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
ES2138624T3 (es) 1992-05-13 2000-01-16 Wellcome Found Combinaciones terapeuticas.
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
IL148685A0 (en) 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
HUP0302631A2 (hu) 2000-03-30 2003-11-28 Bristol-Myers Squibb Co. Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
KR20040025880A (ko) 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 수용해성이 개선된 의약 조성물
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
WO2004043433A2 (en) 2002-11-08 2004-05-27 Glaxo Group Limited Pharmaceutical antiviral compositions
CA2506316A1 (en) 2002-11-15 2004-06-03 Tibotec Pharmaceuticals Ltd. Substituted indolepyridinium as anti-infective compounds
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
AU2005253957B2 (en) 2004-06-08 2011-08-25 Janssen Pharmaceutica Nv Pharmaceutical compositions
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
BRPI0514871A (pt) 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
BRPI0518187A (pt) 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
JP2008538754A (ja) * 2005-04-11 2008-11-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 薬剤を含んだ所定のレイヤパターンを有する複層構造体
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
CN101272848B (zh) 2005-07-28 2013-03-13 Isp投资有限公司 改进喷雾干燥的粉末和颗粒材料性质的方法，以及由此生产的产品
CN103877091A (zh) 2006-01-20 2014-06-25 泰博特克药品有限公司 用tcm278对hiv感染进行的长期治疗
DK2040671T3 (en) 2006-06-23 2018-05-07 Janssen Sciences Ireland Uc AURAL SUSPENSIONS OF TMC278
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
SI2175857T1 (sl) 2007-07-12 2014-01-31 Janssen R&D Ireland Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
US20110257111A1 (en) * 2008-10-24 2011-10-20 Harbeson Scott L Hydroxyethlamino Sulfonamide Derivatives

Also Published As

Publication number Publication date
US20170100398A1 (en) 2017-04-13
CY2015038I2 (el) 2016-08-31
NO2016025I1 (xx) 2016-12-20
LU92853I2 (fr) 2015-12-21
FR15C0072I1 (xx) 2015-04-12
MXPA06002437A (es) 2006-06-20
CY2016048I1 (el) 2017-07-12
LU92855I2 (fr) 2015-12-21
NO2014032I1 (no) 2015-01-05
US8841310B2 (en) 2014-09-23
US20100029591A1 (en) 2010-02-04
CY2016049I2 (el) 2017-07-12
EP1663240B1 (en) 2015-04-22
IL173438A0 (en) 2006-06-11
US20180228800A1 (en) 2018-08-16
US20200171027A1 (en) 2020-06-04
LU92854I2 (fr) 2015-12-21
NL300768I1 (xx) 2015-12-16
AP2006003551A0 (en) 2006-04-30
AP2109A (en) 2010-02-26
AU2014203484A1 (en) 2014-07-17
FR15C0071I2 (fr) 2016-02-12
NL300781I1 (xx) 2016-04-19
FR15C0073I1 (xx) 2015-04-12
IL213104A0 (en) 2011-07-31
PL1663240T5 (pl) 2024-02-26
EP1663240B2 (en) 2023-03-01
NL300768I2 (nl) 2023-08-09
NO2014030I2 (no) 2014-12-18
AU2019200813A1 (en) 2019-02-28
JP2015044839A (ja) 2015-03-12
HUS1600058I1 (hu) 2017-02-28
NO2014032I2 (no) 2014-12-18
MY169670A (en) 2019-05-08
JP5507791B2 (ja) 2014-05-28
US20150283135A1 (en) 2015-10-08
NO2014030I1 (no) 2015-01-05
KR20060090658A (ko) 2006-08-14
JP5820045B2 (ja) 2015-11-24
JP2007520443A (ja) 2007-07-26
HUS1500054I1 (hu) 2016-03-29
CY2015040I1 (el) 2016-08-31
US20220008417A1 (en) 2022-01-13
CA2537095A1 (en) 2005-03-10
AU2014203484B2 (en) 2016-09-29
HUS1500052I1 (hu) 2016-03-29
JP2012051915A (ja) 2012-03-15
IL213104A (en) 2016-02-29
CY2016048I2 (el) 2017-07-12
AU2011201123A1 (en) 2011-04-07
CY2015039I2 (el) 2016-08-31
NO20061374L (no) 2006-03-27
NO2016026I1 (no) 2016-12-20
AU2004268390B2 (en) 2011-03-31
WO2005021001A1 (en) 2005-03-10
AU2016210733A1 (en) 2016-08-25
CA2537095C (en) 2012-05-29
LTC1663240I2 (lt) 2022-05-25
US20140349971A1 (en) 2014-11-27
NO2014031I1 (no) 2015-01-05
IL173438A (en) 2012-03-29
CY2016049I1 (el) 2017-07-12
FR15C0071I1 (xx) 2015-04-12
AU2016210733B2 (en) 2018-11-08
LTPA2016045I1 (lt) 2017-01-10
NZ545306A (en) 2009-11-27
PL1663240T3 (pl) 2015-10-30
CY2015039I1 (el) 2016-08-31
HUS1500053I1 (hu) 2016-03-29
EP1663240A1 (en) 2006-06-07
AU2011201123B2 (en) 2013-10-10
FI1663240T4 (fi) 2023-04-25
LTPA2016044I1 (lt) 2017-01-10
HRP20150798T4 (hr) 2023-06-09
AU2004268390A1 (en) 2005-03-10
US20190216807A1 (en) 2019-07-18
FR15C0072I2 (fr) 2019-05-17
CN101060844A (zh) 2007-10-24
NL300781I2 (xx) 2016-04-19
US20080200435A1 (en) 2008-08-21
CN101060844B (zh) 2012-01-04
CY2015040I2 (el) 2016-08-31
NO334877B1 (no) 2014-06-23
HRP20150798T1 (hr) 2015-09-11
HUS1600059I1 (hu) 2017-02-28
CY2015038I1 (el) 2016-08-31
NO2014031I2 (no) 2014-12-18
BE2015C053I2 (xx) 2023-12-14
HK1092698A1 (en) 2007-02-16

Similar Documents

Publication Publication Date Title
FR15C0073I2 (fr) Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
DE602004008227D1 (de) Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase
LTPA2016046I1 (lt) Modifikuoti fluorintų nukleozidų analogai
MA28695B1 (fr) Derives pyrimidines uree en tant qu'inhibiteurs de kinase
FR12C0035I2 (fr) Derives de pyrimidines inhibiteurs de vih
HK1080849A1 (en) Non-nucleoside reverse transcriptase inhibitors
BRPI0516242A (pt) compostos tieno-pirimidina tendo atividade fungicida
AU2003233667A8 (en) Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
ITMI20031847A1 (it) Composizione di fluoropolimeri espandibili senza l'impiego di agenti espandenti.
ATE390425T1 (de) Xanthin-phosphodiesterase-v-hemmer polymorphe
ITTO20020867A1 (it) Schienale di sedia.
IL157543A0 (en) Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
IL160627A0 (en) Urea and thiourea derivatives as non-nucleoside reverse transcriptase inhibitors
ITTN20020008U1 (it) Predisposizione rapida per ancoraggio o altro nella costruzione di fori in terreni difficoltosi
EA200600522A1 (ru) Комбинации пиримидинсодержащего nnrti с ингибиторами обратной транскриптазы
ITTO20020078A1 (it) Accessorio per l'avvitamento e svitamento di tasselli e simili.
BRPI0414027A (pt) combinações de uma pirimidina que contêm nnrti com inibidores de tr